Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Related Citations for PubMed (Select 18420139)

1.

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR.

Chem Biol. 2008 Apr;15(4):322-31. doi: 10.1016/j.chembiol.2008.03.005.

2.

An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.

Viaud J, Peterson JR.

Mol Cancer Ther. 2009 Sep;8(9):2559-65. doi: 10.1158/1535-7163.MCT-09-0102. Epub 2009 Sep 1.

3.

PAK'n it in: identification of a selective PAK inhibitor.

Bokoch GM.

Chem Biol. 2008 Apr;15(4):305-6. doi: 10.1016/j.chembiol.2008.03.011.

4.

p21-activated kinase inhibitors.

Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J.

Enzymes. 2013;34 Pt. B:157-80. doi: 10.1016/B978-0-12-420146-0.00007-X. Epub 2013 Nov 7. Review.

PMID:
25034104
5.

FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S, Campbell D, Chernoff J, Field J, Marmorstein R, Kissil JL.

J Biol Chem. 2013 Oct 4;288(40):29105-14. doi: 10.1074/jbc.M113.510933. Epub 2013 Aug 19.

6.

IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation.

Wong LL, Lam IP, Wong TY, Lai WL, Liu HF, Yeung LL, Ching YP.

PLoS One. 2013 Jul 19;8(7):e68843. doi: 10.1371/journal.pone.0068843. Print 2013.

7.

Group I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cells.

Kuželová K, Grebeňová D, Holoubek A, Röselová P, Obr A.

PLoS One. 2014 Mar 24;9(3):e92560. doi: 10.1371/journal.pone.0092560. eCollection 2014.

8.

Inhibition of p21 activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways.

Hoover WC, Zhang W, Xue Z, Gao H, Chernoff J, Clapp DW, Gunst SJ, Tepper RS.

PLoS One. 2012;7(8):e42601. doi: 10.1371/journal.pone.0042601. Epub 2012 Aug 10.

9.

Identification of allosteric inhibitors of p21-activated kinase.

Viaud J, Peterson JR.

Methods Mol Biol. 2012;928:67-79. doi: 10.1007/978-1-62703-008-3_6.

PMID:
22956134
10.

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.

Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7177-82. doi: 10.1073/pnas.1103350108. Epub 2011 Apr 11.

11.

ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.

Yuan L, Santi M, Rushing EJ, Cornelison R, MacDonald TJ.

Clin Exp Metastasis. 2010 Oct;27(7):481-91. doi: 10.1007/s10585-010-9337-9. Epub 2010 Jun 6.

12.

A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids.

Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, Knaus UG.

J Biol Chem. 1998 Apr 3;273(14):8137-44.

13.

PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.

Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO.

Exp Neurol. 2009 Jul;218(1):137-44. doi: 10.1016/j.expneurol.2009.04.019. Epub 2009 May 3.

14.

p21-Activated kinase inhibitors: a patent review.

Crawford JJ, Hoeflich KP, Rudolph J.

Expert Opin Ther Pat. 2012 Mar;22(3):293-310. doi: 10.1517/13543776.2012.668758. Epub 2012 Mar 11. Review.

PMID:
22404134
15.

Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.

Ma Y, McCarty SK, Kapuriya NP, Brendel VJ, Wang C, Zhang X, Jarjoura D, Saji M, Chen CS, Ringel MD.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1314-22. doi: 10.1210/jc.2012-3937. Epub 2013 May 24.

16.

Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.

Simard JR, Getlik M, Grütter C, Pawar V, Wulfert S, Rabiller M, Rauh D.

J Am Chem Soc. 2009 Sep 23;131(37):13286-96. doi: 10.1021/ja902010p.

PMID:
19572644
17.

2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.

Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, Kulp SK, Kirschner LS, Saji M, Chen CS, Ringel MD.

Mol Pharmacol. 2007 Nov;72(5):1124-31. Epub 2007 Aug 2.

18.

Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors.

Beeser A, Jaffer ZM, Hofmann C, Chernoff J.

J Biol Chem. 2005 Nov 4;280(44):36609-15. Epub 2005 Aug 29.

19.

Regulation of macropinocytosis by p21-activated kinase-1.

Dharmawardhane S, Schürmann A, Sells MA, Chernoff J, Schmid SL, Bokoch GM.

Mol Biol Cell. 2000 Oct;11(10):3341-52.

20.

Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.

Menges CW, Sementino E, Talarchek J, Xu J, Chernoff J, Peterson JR, Testa JR.

Mol Cancer Res. 2012 Sep;10(9):1178-88. Epub 2012 Jul 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk